Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
Public ClinicalTrials.gov record NCT01756157. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Study identification
- NCT ID
- NCT01756157
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Shire
- Industry
- Enrollment
- 47 participants
Conditions and interventions
Conditions
Interventions
- CINRYZE with rHuPH20 Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2013
- Primary completion
- Sep 12, 2013
- Completion
- Sep 12, 2013
- Last update posted
- Jun 2, 2021
2013
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ViroPharma Investigational Site | Birmingham | Alabama | 35209 | — |
| ViroPharma Investigational Site | Scottsdale | Arizona | 85251 | — |
| ViroPharma Investigational Site | Bentonville | Arkansas | 72712 | — |
| ViroPharma Investigational Site | Walnut Creek | California | 94598 | — |
| ViroPharma Investigational Site | Colorado Springs | Colorado | 80907 | — |
| ViroPharma Investigational Site | Tampa | Florida | 33613 | — |
| ViroPharma Investigational Site | Boston | Massachusetts | 02114 | — |
| ViroPharma Investigational Site | Las Vegas | Nevada | 89106 | — |
| ViroPharma Investigational Site | Mineola | New York | 11501 | — |
| ViroPharma Investigational Site | Cincinnati | Ohio | 45267 | — |
| ViroPharma Investigational Site | Columbus | Ohio | 43235 | — |
| ViroPharma Investigational Site | Lake Oswego | Oregon | 97035 | — |
| ViroPharma Investigational Site | Hershey | Pennsylvania | 17033 | — |
| ViroPharma Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| ViroPharma Investigational Site | Knoxville | Tennessee | 37909 | — |
| ViroPharma Investigational Site | Dallas | Texas | 75231 | — |
| ViroPharma Investigational Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01756157, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01756157 live on ClinicalTrials.gov.